AP NEWS

CytomX to Present at Upcoming Healthcare Conferences

September 25, 2018

SOUTH SAN FRANCISCO, Calif., Sept. 25, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on our Probody™ therapeutic technology platform, announced today that members of its senior management team will participate at the following healthcare at conferences in October.

Third Annual FierceBiotech Drug Development Forum

Date: Tuesday, October 2, 2018 Location: Boston, Massachusetts

-- Sean McCarthy, D.Phil., chief executive officer, will participate in the panel discussion “Develop Combination Therapies for Immuno-Oncology” -- Debanjan Ray, chief financial officer, will participate in the panel discussion “Update Collaboration Models Between Pharma and Biotech”

Cantor Fitzgerald Global Healthcare Conference

Date: Wednesday, October 3, 2018 Time: 1:05pm EDT Location: New York, New York

A live audio webcast of the Cantor presentation will be available through the Investors and News section of CytomX’s website. An archived replay will be available for 90 days following the event.

About CytomX Therapeutics

CytomX Therapeutics is a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology platform. Probody therapeutics are designed to exploit unique conditions of the tumor microenvironment to more effectively localize antibody binding and activity while limiting activity in healthy tissues. The Company’s pipeline includes cancer immunotherapies against clinically-validated targets, including a PD-L1-targeting Probody therapeutic wholly owned by CytomX (CX-072), a PD-1-targeting Probody therapeutic wholly owned by CytomX (CX-188) and a CTLA-4-targeting Probody therapeutic partnered with Bristol Myers Squibb (BMS-986249). The pipeline also includes first-in-class Probody drug conjugates against highly attractive targets including a CD166-targeting Probody drug conjugate wholly owned by CytomX (CX-2009), and a CD71-targeting Probody drug conjugate partnered with AbbVie (CX-2029) are among cancer targets that have been considered to be inaccessible to conventional antibody drug conjugates due to their presence on many healthy tissues. CytomX and its partners have four programs in the clinic. In addition to its wholly owned programs, CytomX has strategic collaborations with AbbVie, Amgen, Bristol-Myers Squibb Company and ImmunoGen, Inc. For more information, visit www.cytomx.com.

Contact: Investors and Media: Christopher Keenan VP, Investor Relations and Corporate Communications ckeenan@cytomx.com 650-383-0823

AP RADIO
Update hourly